Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
Seeking Alpha on MSN1h
Novo's Rybelsus results may not be clinically meaningful, Bernstein saysBernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...
Novo Nordisk, a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its ...
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
Zacks.com on MSN8h
5 Large Drug Stocks Likely to Outpace Q3 Earnings EstimatesLet us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...
For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...
Mangoceuticals (NASDAQ:MGRX), which operates the men’s health platform MangoRx, said it strongly refutes any and all claims ...
The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback